1 EXECUTIVE SUMMARY
1.1 OVERVIEW 18
1.2 MARKET SYNOPSIS 18
1.3 KEY CONTRIBUTING FACTORS 19
2 MARKET INTRODUCTION
2.1 DEFINITION 20
2.2 SCOPE OF THE STUDY 20
2.3 RESEARCH OBJECTIVE 20
2.4 MARKET STRUCTURE 21
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS 22
3.2 PRIMARY RESEARCH 24
3.3 SECONDARY RESEARCH 25
3.4 MARKET SIZE ESTIMATION 25
3.5 FORECAST MODEL 27
3.6 LIST OF ASSUMPTIONS 28
4 MARKET DYNAMICS
4.1 OVERVIEW 29
4.2 DRIVERS 30
4.2.1 HIGH INCIDENCE OF OSTEOSARCOMA 30
4.2.2 RISING EXPENDITURE ON ONCOLOGY MEDICINE AND RESEARCH 30
4.2.3 RISING DEMAND FOR NEW TREATMENTS 30
4.3 RESTRAINTS 31
4.3.1 HIGH COST OF TREATMENT 31
4.3.2 SIDE-EFFECTS OF CHEMOTHERAPY 31
4.4 OPPORTUNITIES 32
4.4.1 ENTERING DEVELOPING ECONOMIES 32
4.5 MACROECONOMIC INDICATORS 33
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 34
5.1.1 BARGAINING POWER OF SUPPLIERS 35
5.1.2 BARGAINING POWER OF BUYERS 35
5.1.3 THREAT OF NEW ENTRANTS 35
5.1.4 THREAT OF SUBSTITUTES 35
5.1.5 INTENSITY OF RIVALRY 35
5.2 VALUE CHAIN ANALYSIS 36
5.2.1 R&D AND DESIGNING 37
5.2.2 MANUFACTURING 37
5.2.3 DISTRIBUTION 37
5.2.4 MARKETING & SALES 37
5.2.5 POST-SALES MONITORING 37
5.3 EPIDEMIOLOGY DATA 38
5.4 CLINICAL TRIALS ANALYSIS 39
5.5 PIPELINE ANALYSIS 41
5.5.1 PEMETREXED 41
5.5.2 INHALED LIPID CISPLATIN 41
6 OSTEOSARCOMA MARKET, BY TYPE
6.1 OVERVIEW 42
6.2 INTRAMEDULLARY OSTEOSARCOMA 43
6.3 JUXTACORTICAL OSTEOSARCOMA 44
6.4 EXTRASKELETAL OSTEOSARCOMA 44
7 OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
7.1 OVERVIEW 45
7.2 TREATMENT 46
7.2.1 CHEMOTHERAPY 47
7.2.2 SURGERY 47
7.2.3 RADIATION THERAPY 47
7.3 DIAGNOSIS 48
7.3.1 IMAGING 48
7.3.2 BIOPSIES 49
7.3.3 BLOOD TESTS 50
8 OSTEOSARCOMA MARKET, BY END USER
8.1 OVERVIEW 51
8.2 HOSPITALS & CLINICS 52
8.3 DIAGNOSTIC CENTERS 52
8.4 ACADEMIC & RESEARCH ORGANIZATIONS 53
9 GLOBAL OSTEOSARCOMA MARKET, BY REGION
9.1 OVERVIEW 54
9.2 AMERICAS 56
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.2.1 NORTH AMERICA 60
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.2.1.1 US 63
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.2.1.2 US: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 65
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.2.1.3 CANADA 66
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.2.2 LATIN AMERICA 69
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.3 EUROPE 73
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.3.1 WESTERN EUROPE 76
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.3.1.1 GERMANY 80
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.3.1.2 FRANCE 83
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.3.1.3 UK 86
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.3.1.4 ITALY 89
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.3.1.5 SPAIN 92
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.3.1.6 REST OF WESTERN EUROPE 95
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.3.2 EASTERN EUROPE 99
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.4 ASIA-PACIFIC 103
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.4.1 JAPAN 107
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.4.2 CHINA 110
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.4.3 INDIA 113
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.4.4 SOUTH KOREA 116
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.4.5 REST OF ASIA-PACIFIC 119
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.5 MIDDLE EAST & AFRICA 123
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.5.1 MIDDLE EAST 127
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
9.5.2 AFRICA 130
OSTEOSARCOMA MARKET, BY TYPE
OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
OSTEOSARCOMA MARKET, BY END USER
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 134
10.2 KEY DEVELOPMENTS 134
11 COMPANY PROFILES
11.1 PFIZER INC. 136
11.1.1 COMPANY OVERVIEW 136
11.1.2 FINANCIAL OVERVIEW 137
11.1.3 PRODUCTS/SERVICES OFFERED 137
11.1.4 KEY DEVELOPMENTS 138
11.1.5 SWOT ANALYSIS 138
11.1.6 KEY STRATEGIES 138
11.2 BRISTOL-MYERS SQUIBB COMPANY 139
11.2.1 COMPANY OVERVIEW 139
11.2.2 FINANCIAL OVERVIEW 139
11.2.3 PRODUCTS/SERVICES OFFERED 140
11.2.4 KEY DEVELOPMENTS 140
11.2.5 SWOT ANALYSIS 140
11.2.6 EY STRATEGIES 141
11.3 ELI LILLY AND COMPANY 142
11.3.1 COMPANY OVERVIEW 142
11.3.2 FINANCIAL OVERVIEW 143
11.3.3 PRODUCTS/SERVICES OFFERED 143
11.3.4 KEY DEVELOPMENTS 143
11.3.5 SWOT ANALYSIS 144
11.3.6 KEY STRATEGIES 144
11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD 145
11.4.1 COMPANY OVERVIEW 145
11.4.2 FINANCIAL OVERVIEW 146
11.4.3 PRODUCTS/SERVICES OFFERED 146
11.4.4 KEY DEVELOPMENTS 146
11.4.5 SWOT ANALYSIS 147
11.4.6 KEY STRATEGIES 147
11.5 BAXTER INTERNATIONAL 148
11.5.1 COMPANY OVERVIEW 148
11.5.2 FINANCIAL OVERVIEW 148
11.5.3 PRODUCTS/SERVICES OFFERED 149
11.5.4 KEY DEVELOPMENTS 149
11.5.5 SWOT ANALYSIS 150
11.5.6 KEY STRATEGIES 150
11.6 NOVARTIS AG 151
11.6.1 COMPANY OVERVIEW 151
11.6.2 FINANCIAL OVERVIEW 151
11.6.3 PRODUCTS/SERVICES OFFERED 152
11.6.4 KEY DEVELOPMENTS 152
11.6.5 SWOT ANALYSIS 153
11.6.6 KEY STRATEGIES 153
11.7 AUROBINDO PHARMA LIMITED 154
11.7.1 COMPANY OVERVIEW 154
11.7.2 FINANCIAL OVERVIEW 154
11.7.3 PRODUCTS/SERVICES OFFERED 155
11.7.4 KEY DEVELOPMENTS 155
11.7.5 SWOT ANALYSIS 156
11.7.6 KEY STRATEGIES 156
11.8 HIKMA PHARMACEUTICALS PLC 157
11.8.1 COMPANY OVERVIEW 157
11.8.2 FINANCIAL OVERVIEW 157
11.8.3 PRODUCTS/SERVICES OFFERED 158
11.8.4 KEY DEVELOPMENTS 158
11.8.5 SWOT ANALYSIS 159
11.8.6 KEY STRATEGIES 159
11.9 MYLAN NV 160
11.9.1 COMPANY OVERVIEW 160
11.9.2 FINANCIAL OVERVIEW 161
11.9.3 PRODUCTS/SERVICES OFFERED 162
11.9.4 KEY DEVELOPMENTS 162
11.9.5 SWOT ANALYSIS 163
11.9.6 KEY STRATEGIES 163
11.10 ADVAXIS, INC. 164
11.10.1 COMPANY OVERVIEW 164
11.10.2 FINANCIAL OVERVIEW 164
11.10.3 PRODUCTS/SERVICES OFFERED 164
11.10.4 KEY DEVELOPMENTS 165
11.10.5 SWOT ANALYSIS 165
11.10.6 KEY STRATEGIES 166
12 APPENDIX
12.1 REFERENCES 167
12.2 RELATED REPORTS 167
13 LIST OF TABLES
TABLE 1 PRIMARY INTERVIEWS 24
TABLE 2 LIST OF ASSUMPTIONS 28
TABLE 3 INCIDENCE OF OSTEOSARCOMA, BY AGE IN THE US 38
TABLE 4 CLINICAL TRIALS 39
TABLE 5 PIPELINE ANALYSIS 41
TABLE 6 GLOBAL OSTEOSARCOMA MARKET, BY TYPE 2020–2027 (USD MILLION) 42
TABLE 7 GLOBAL INTRAMEDULLARY OSTEOSARCOMA: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 43
TABLE 8 GLOBAL JUXTACORTICAL OSTEOSARCOMA: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 44
TABLE 9 GLOBAL EXTRASKELETAL OSTEOSARCOMA: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 44
TABLE 10 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 45
TABLE 11 GLOBAL TREATMENT: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 46
TABLE 12 GLOBAL TREATMENT: MARKET ESTIMATES & FORECAST, BY TYPE, 2020–2027 (USD MILLION) 46
TABLE 13 GLOBAL CHEMOTHERAPY: MARKET ESTIMATES & FORECAST, BY TYPE, 2020–2027 (USD MILLION) 47
TABLE 14 GLOBAL SURGERY: MARKET ESTIMATES & FORECAST, BY TYPE, 2020–2027 (USD MILLION) 47
TABLE 15 GLOBAL DIAGNOSIS: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 48
TABLE 16 GLOBAL DIAGNOSIS: MARKET ESTIMATES & FORECAST, BY TYPE, 2020–2027 (USD MILLION) 48
TABLE 17 GLOBAL IMAGING: MARKET ESTIMATES & FORECAST, BY TYPE, 2020–2027 (USD MILLION) 49
TABLE 18 GLOBAL BIOPSIES: MARKET ESTIMATES & FORECAST, BY TYPE, 2020–2027 (USD MILLION) 49
TABLE 19 GLOBAL BLOOD TESTS: MARKET ESTIMATES & FORECAST, BY TYPE, 2020–2027 (USD MILLION) 50
TABLE 20 GLOBAL OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 51
TABLE 21 GLOBAL HOSPITALS & CLINICS: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 52
TABLE 22 GLOBAL DIAGNOSTIC CENTERS: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 53
TABLE 23 GLOBAL ACADEMIC INSTITUTES & RESEARCH ORGANIZATIONS: MARKET ESTIMATES & FORECAST, BY REGION, 2020–2027 (USD MILLION) 53
TABLE 24 GLOBAL OSTEOSARCOMA MARKET, BY REGION, 2020–2027 (USD MILLION) 55
TABLE 25 AMERICAS: OSTEOSARCOMA MARKET, BY REGION, 2020–2027 (USD MILLION) 56
TABLE 26 AMERICAS: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 56
TABLE 27 AMERICAS: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 57
TABLE 28 AMERICAS: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 57
TABLE 29 AMERICAS: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 57
TABLE 30 AMERICAS: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 58
TABLE 31 AMERICAS: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 58
TABLE 32 AMERICAS: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 58
TABLE 33 AMERICAS: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 59
TABLE 34 AMERICAS: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 59
TABLE 35 AMERICAS: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 59
TABLE 36 NORTH AMERICA: OSTEOSARCOMA MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 60
TABLE 37 NORTH AMERICA: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 60
TABLE 38 NORTH AMERICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 60
TABLE 39 NORTH AMERICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 61
TABLE 40 NORTH AMERICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 61
TABLE 41 NORTH AMERICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 61
TABLE 42 NORTH AMERICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 62
TABLE 43 NORTH AMERICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 62
TABLE 44 NORTH AMERICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 62
TABLE 45 NORTH AMERICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 63
TABLE 46 NORTH AMERICA: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 63
TABLE 47 US: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 63
TABLE 48 US: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 64
TABLE 49 US: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 64
TABLE 50 US: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 64
TABLE 51 US: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 64
TABLE 52 US: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 65
TABLE 53 US: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 65
TABLE 54 US: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 66
TABLE 55 US: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 66
TABLE 56 CANADA: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 66
TABLE 57 CANADA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 67
TABLE 58 CANADA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 67
TABLE 59 CANADA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 67
TABLE 60 CANADA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 67
TABLE 61 CANADA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 68
TABLE 62 CANADA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 68
TABLE 63 CANADA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 68
TABLE 64 CANADA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 69
TABLE 65 CANADA: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 69
TABLE 66 LATIN AMERICA: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 69
TABLE 67 LATIN AMERICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 70
TABLE 68 LATIN AMERICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 70
TABLE 69 LATIN AMERICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 70
TABLE 70 LATIN AMERICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 70
TABLE 71 LATIN AMERICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 71
TABLE 72 LATIN AMERICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 71
TABLE 73 LATIN AMERICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 71
TABLE 74 LATIN AMERICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 72
TABLE 75 LATIN AMERICA: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 72
TABLE 76 EUROPE: OSTEOSARCOMA MARKET, BY REGION, 2020–2027 (USD MILLION) 73
TABLE 77 EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 73
TABLE 78 EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 74
TABLE 79 EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 74
TABLE 80 EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 74
TABLE 81 EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 74
TABLE 82 EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 75
TABLE 83 EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 75
TABLE 84 EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 75
TABLE 85 EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 76
TABLE 86 EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 76
TABLE 87 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 88 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 89 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 77
TABLE 90 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 91 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 78
TABLE 92 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 78
TABLE 93 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 78
TABLE 94 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 79
TABLE 95 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 79
TABLE 96 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 79
TABLE 97 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 80
TABLE 98 GERMANY: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 80
TABLE 99 GERMANY: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 80
TABLE 100 GERMANY: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 81
TABLE 101 GERMANY: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 81
TABLE 102 GERMANY: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 81
TABLE 103 GERMANY: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 82
TABLE 104 GERMANY: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 82
TABLE 105 GERMANY: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 82
TABLE 106 GERMANY: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 83
TABLE 107 GERMANY: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 83
TABLE 108 FRANCE: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 83
TABLE 109 FRANCE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 84
TABLE 110 FRANCE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 111 FRANCE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 112 FRANCE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 113 FRANCE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 85
TABLE 114 FRANCE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 85
TABLE 115 FRANCE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 85
TABLE 116 FRANCE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 86
TABLE 117 FRANCE: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 86
TABLE 118 UK: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 119 UK: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 87
TABLE 120 UK: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 121 UK: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 122 UK: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 123 UK: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 88
TABLE 124 UK: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 88
TABLE 125 UK: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 88
TABLE 126 UK: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 89
TABLE 127 UK: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 89
TABLE 128 ITALY: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 129 ITALY: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 90
TABLE 130 ITALY: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 90
TABLE 131 ITALY: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 90
TABLE 132 ITALY: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 90
TABLE 133 ITALY: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 91
TABLE 134 ITALY: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 91
TABLE 135 ITALY: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 91
TABLE 136 ITALY: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 92
TABLE 137 ITALY: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 92
TABLE 138 SPAIN: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 139 SPAIN: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 93
TABLE 140 SPAIN: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 93
TABLE 141 SPAIN: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 93
TABLE 142 SPAIN: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 93
TABLE 143 SPAIN: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 94
TABLE 144 SPAIN: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 94
TABLE 145 SPAIN: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 94
TABLE 146 SPAIN: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 95
TABLE 147 SPAIN: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 95
TABLE 148 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 95
TABLE 149 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 96
TABLE 150 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 96
TABLE 151 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 96
TABLE 152 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 97
TABLE 153 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 97
TABLE 154 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 97
TABLE 155 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 98
TABLE 156 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 98
TABLE 157 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 98
TABLE 158 EASTERN EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 99
TABLE 159 EASTERN EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 99
TABLE 160 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 99
TABLE 161 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 100
TABLE 162 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 100
TABLE 163 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 100
TABLE 164 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 101
TABLE 165 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 101
TABLE 166 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 101
TABLE 167 EASTERN EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 102
TABLE 168 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 169 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 104
TABLE 170 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 104
TABLE 171 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 104
TABLE 172 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 173 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 174 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 105
TABLE 175 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 106
TABLE 176 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 106
TABLE 177 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 106
TABLE 178 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 107
TABLE 179 JAPAN: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 107
TABLE 180 JAPAN: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 107
TABLE 181 JAPAN: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 182 JAPAN: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 183 JAPAN: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 184 JAPAN: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 109
TABLE 185 JAPAN: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 109
TABLE 186 JAPAN: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 109
TABLE 187 JAPAN: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 110
TABLE 188 JAPAN: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 110
TABLE 189 CHINA: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 190 CHINA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 111
TABLE 191 CHINA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 192 CHINA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 193 CHINA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 194 CHINA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 112
TABLE 195 CHINA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 112
TABLE 196 CHINA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 112
TABLE 197 CHINA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 113
TABLE 198 CHINA: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 113
TABLE 199 INDIA: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 113
TABLE 200 INDIA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 114
TABLE 201 INDIA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 202 INDIA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 203 INDIA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 204 INDIA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 115
TABLE 205 INDIA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 115
TABLE 206 INDIA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 115
TABLE 207 INDIA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 116
TABLE 208 INDIA: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 116
TABLE 209 SOUTH KOREA: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 210 SOUTH KOREA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 117
TABLE 211 SOUTH KOREA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 212 SOUTH KOREA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 213 SOUTH KOREA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 214 SOUTH KOREA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 118
TABLE 215 SOUTH KOREA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 118
TABLE 216 SOUTH KOREA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 118
TABLE 217 SOUTH KOREA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 119
TABLE 218 SOUTH KOREA: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 119
TABLE 219 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 220 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 120
TABLE 221 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 222 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 223 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 224 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 121
TABLE 225 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 121
TABLE 226 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 122
TABLE 227 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 122
TABLE 228 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 122
TABLE 229 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY REGION, 2020–2027 (USD MILLION) 123
TABLE 230 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 231 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 124
TABLE 232 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 233 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 234 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 235 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 125
TABLE 236 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 125
TABLE 237 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 126
TABLE 238 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 126
TABLE 239 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 126
TABLE 240 MIDDLE EAST: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 241 MIDDLE EAST: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 127
TABLE 242 MIDDLE EAST: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 243 MIDDLE EAST: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 244 MIDDLE EAST: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 245 MIDDLE EAST: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 128
TABLE 246 MIDDLE EAST: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 129
TABLE 247 MIDDLE EAST: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 129
TABLE 248 MIDDLE EAST: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 129
TABLE 249 MIDDLE EAST: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 130
TABLE 250 AFRICA: OSTEOSARCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 251 AFRICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 130
TABLE 252 AFRICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 253 AFRICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 254 AFRICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 255 AFRICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 132
TABLE 256 AFRICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2020–2027 (USD MILLION) 132
TABLE 257 AFRICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2020–2027 (USD MILLION) 132
TABLE 258 AFRICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2020–2027 (USD MILLION) 133
TABLE 259 AFRICA: OSTEOSARCOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 133
TABLE 260 MAJOR MANUFACTURERS IN THE GLOBAL OSTEOSARCOMA MARKET 134
TABLE 261 KEY DEVELOPMENTS BY PLAYERS IN THE MARKET 135
TABLE 262 PFIZER INC.: PRODUCTS/SERVICES OFFERED 137
TABLE 263 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED 140
TABLE 264 ELI LILLY AND COMPANY: PRODUCTS OFFERED 143
TABLE 265 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED 146
TABLE 266 BAXTER INTERNATIONAL: PRODUCTS/SERVICES OFFERED 149
TABLE 267 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 152
TABLE 268 AUROBINDO PHARMA LIMITED: PRODUCTS/SERVICES OFFERED 155
TABLE 269 AUROBINDO PHARMA LIMITED: KEY DEVELOPMENTS 155
TABLE 270 HIKMA PHARMACEUTICALS PLC: PRODUCTS OFFERED 158
TABLE 271 HIKMA PHARMACEUTICALS PLC: KEY DEVELOPMENTS 158
TABLE 272 MYLAN NV: PRODUCTS/SERVICES OFFERED 162
TABLE 273 ADVAXIS, INC.: PRODUCTS/SERVICES OFFERED 164
TABLE 274 ADVAXIS, INC.: KEY DEVELOPMENTS 165
14 LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 18
FIGURE 2 GLOBAL OSTEOSARCOMA MARKET: STRUCTURE 21
FIGURE 3 RESEARCH PROCESS 23
FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACHES 26
FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL OSTEOSARCOMA MARKET 29
FIGURE 6 DRIVERS: IMPACT ANALYSIS 31
FIGURE 7 RESTRAINTS: IMPACT ANALYSIS 32
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL OSTEOSARCOMA MARKET 34
FIGURE 9 VALUE CHAIN ANALYSIS OF THE GLOBAL OSTEOSARCOMA MARKET 36
FIGURE 10 PIPELINE ANALYSIS 41
FIGURE 11 GLOBAL OSTEOSARCOMA MARKET, BY TYPE, 2020 (% SHARE) 42
FIGURE 12 GLOBAL OSTEOSARCOMA MARKET, BY TYPE, 2020 TO 2027 (USD MILLION) 43
FIGURE 13 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2020 (% SHARE) 45
FIGURE 14 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 46
FIGURE 15 GLOBAL OSTEOSARCOMA MARKET, BY END USER, 2020 (% SHARE) 51
FIGURE 16 GLOBAL OSTEOSARCOMA MARKET, BY END USER, 2020 TO 2027 (USD MILLION) 52
FIGURE 17 GLOBAL OSTEOSARCOMA MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 54
FIGURE 18 GLOBAL OSTEOSARCOMA MARKET, BY REGION, 2020 (% SHARE) 54
FIGURE 19 AMERICAS: OSTEOSARCOMA MARKET SHARE, BY REGION, 2020 (% SHARE) 56
FIGURE 20 EUROPE: OSTEOSARCOMA MARKET SHARE, BY REGION, 2020 (% SHARE) 73
FIGURE 21 ASIA-PACIFIC: OSTEOSARCOMA MARKET SHARE, BY COUNTRY, 2020 (% SHARE) 103
FIGURE 22 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET SHARE, BY REGION, 2020 (% SHARE) 123
FIGURE 23 PFIZER INC. FINANCIAL OVERVIEW SNAPSHOT 137
FIGURE 24 PFIZER INC.: SWOT ANALYSIS 138
FIGURE 25 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT 139
FIGURE 26 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS 140
FIGURE 27 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 143
FIGURE 28 ELI LILLY AND COMPANY: SWOT ANALYSIS 144
FIGURE 29 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 146
FIGURE 30 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 147
FIGURE 31 BAXTER INTERNATIONAL: FINANCIAL OVERVIEW SNAPSHOT 148
FIGURE 32 BAXTER INTERNATIONAL: SWOT ANALYSIS 150
FIGURE 33 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 151
FIGURE 34 NOVARTIS AG: SWOT ANALYSIS 153
FIGURE 35 AUROBINDO PHARMA LIMITED: FINANCIAL OVERVIEW SNAPSHOT 154
FIGURE 36 AUROBINDO PHARMA LIMITED: SWOT ANALYSIS 156
FIGURE 37 HIKMA PHARMACEUTICALS PLC: FINANCIAL OVERVIEW SNAPSHOT 157
FIGURE 38 HIKMA PHARMACEUTICALS PLC: SWOT ANALYSIS 159
FIGURE 39 MYLAN NV: FINANCIAL OVERVIEW SNAPSHOT 161
FIGURE 40 MYLAN NV: SWOT ANALYSIS 163
FIGURE 41 ADVAXIS, INC.: FINANCIAL OVERVIEW SNAPSHOT 164
FIGURE 42 ADVAXIS, INC.: SWOT ANALYSIS 165